Details of the Drug
General Information of Drug (ID: DM6BNQR)
Drug Name |
NORBOLDINE
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Laurolitsine; 5890-18-6; Laurolistine; Norboldine; UNII-5MT88IS14F; 1,10-Dimethoxy-6a-alpha-noraporphine-2,9-diol; Dimethoxy-1,10 dihydroxy-2,9 nor-aporphine; 4H-Dibenzo(de,g)quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-; CHEMBL487388; 5MT88IS14F; CHEBI:66557; (6aS)-1,10-dimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol; Dimethoxy-1,10 dihydroxy-2,9 nor-aporphine [French]; 6a-alpha-NORAPORPHINE-2,9-DIOL, 1,10-DIMETHOXY-; (+)-Norboldine; 568-39-8; [(+)-norboldine]; AC1L2JVN; DTXSID30207641
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 313.3 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 2.3 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 3 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References